A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis.
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 15 Dec 2017 Planned number of patients changed from 245 to 105.
- 24 Jul 2017 Planned primary completion date changed from 28 Jun 2018 to 5 May 2021.
- 23 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jul 2021.